During cold storage of donor hearts, reactive oxygen species produced by intracellular redox-active chelatable iron potentially alter myocardial function. To reduce this cold-induced injury we investigated the efficacy of two new modifications of the well established histidine-tryptophan-ketogluterate (HTK) solution (Custodiol ) with the addition of N-a-acetyl-L-histidine and iron-chelators in a heterotopic ᮋ rat heart transplantation model. The donor hearts were cardioplegically arrested with 20 ml cardioplegia and stored for 1 h. Then the hearts were anastomosed to the abdominal aorta and vena cava of the recipient (ns30). After 1 h reperfusion, myocardial function and energy charge potential were measured in three groups: HTK-1: addition of L-arginine and N-a-acetyl-L-histidine; HTK-2: addition of ironchelators deferoxamine and LK-614; traditional HTK -control. After 1 h reperfusion, left ventricular systolic pressure (106"33 vs. 60"39, vs. 67"8 mmHg, P-0.05) and dPydt minimal (-1388"627 vs. -660"446, vs. 871"188 mmHgys, P-0.05) were significantly higher in the HTK-1 group. Energy charge potentials were not significantly different. This study showed that the novel modified HTK-1 solution improves myocardial contractility and relaxation after heart transplantation. Nevertheless, addition of the iron-chelators deferoxamine and LK-614 diminished these beneficial effects.
Introduction
Despite recent efforts of the Eurotransplant foundation to increase the donor pool, the average number of heart transplantations stagnated around 550 per year w1x. An increased clinically acceptable preservation time may be one possibility to widen the donor pool with better preservation techniques. So far, the histidine-tryptophan-ketogluterate (HTK) solution (Custodiol ) was clinically used in ᮋ Europe for effective organ preservation. In clinical heart transplantation an ischemic time of four hours is broadly accepted for HTK preservation w2x. Apart from a cardiomyocyte edema, a specific vulnerability of the vascular endothelium during cold ischemia and postischemic reperfusion has recently been recognized. Endothelial cell damage can limit reperfusion ('no-reflow phenomenon') and may be responsible for the development of graft vasculopathy w3x. During ischemia and reperfusion, endothelial cells are damaged by the production of reactive oxygen species (ROS). The molecular and cellular mechanisms of cold storage endothelial injury have previously been described w4x: the combination of cold storage and the HTK component histidine is responsible for increased intracellular levels of redox-active chelatable iron. Cold activates intracellular chelatable iron, which catalyses the formation of highly toxic ROS as the hydroxyl radical w5, 6x. The *Corresponding author. Tel.: q49 6221 5636191; fax: q49 6221 565585. E-mail address: achim_koch@med.uni-heidelberg.de (A. Koch).
addition of the traditional hydrophilic iron chelator deferoxamine and the newly developed lipophilic, membrane permeable hydroxamic acid derivative LK-614 to preservation solutions were tested with respect to their protective effect in rat heart transplantation. Furthermore, the widely used buffer histidine itself was shown to be cytotoxic via increased intracellular chelatable iron w7, 8x. Recently, another cold-induced injury became apparent, when the stronger iron-dependent component was inhibited. This iron-independent injury can be ameliorated by the reduction of the extracellular chloride concentration in the preservation solution w7, 8x. In the present study we tested to addition of iron chelators deferoxamine and LK-614, andyor partially replacing histidine with N-a-acetyl-L-histidine in chloride poor HTK solutions by evaluating their effect on myocardial function after cold ischemic storage and reperfusion.
Material and methods

Animals
Heterotopic heart transplantation was performed in threemonth-old male Lewis rats (280-400 g; Charles River, Sulzfeld, Germany). The animal care and all experimental procedures were performed in accordance with the animal welfare regulations of the German local authorities, which conform to NIH guidelines wNIH Publication No. 86-23, revised 1996x. 1.7"1.1 0.6"0.5 0.5"0.5 ADP (mmolyg) 3.2"1.9 1.6"0.8 2.1"0.8 AMP (mmolyg) 4.1"2.6 2.2"1.2 8.9"1.8 Energy charge potential 0.36"0.21 0.34"0.26 0.27"0.06
Group HTK: control, 60 min of reperfusion; Group HTK-1: N-a-acetyl-L-histidine treatment, 60 min of reperfusion; Group HTK-2: deferoxamine-, LK-614-treatment, 60 min of reperfusion. HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; dPydt , max maximum rate of pressure development; dPydt , minimum rate of pressure min development; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, adenosine monophosphate. All values are given as mean"S.E.M. Significant P-values are marked by *.
Heterotopic heart transplantation
The rats were anaesthesised with ether. The abdominal cavity of the donor rat was opened and a small arterial cannula placed in the abdominal aorta. Then the thorax was opened with a scissors and the donor hearts were perfused with 20 ml cardioplegic solution within 2-3 min. After ligation of the atria the hearts were explanted and quickly transferred to cold (q48C) storage solution. The donor hearts were explanted and quickly transferred to cold (q48C) storage solution. A number of 10 animals were transplanted per group: HTK-group (Custodiol ), HTK-1-ᮋ group, HTK-2-group ( Table 1) . After 1 h of ischemic preservation, the hearts were implanted intraabdominally anastomosing the aorta and the pulmonary artery of the donor heart with the abdominal aorta of the vena cava of the recipient rat, respectively w9x. Haemodynamic functional assessment was performed after haemodynamic stabilization 60 min after reperfusion. After the functional measurements the hearts were excised for metabolic analysis.
Functional measurements in the graft
Left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP) and rate of pressure development (dPydt) were measured by a Millar pressure catheter (Millar Instruments Inc., Houston, TX, USA). The pressure catheter and a 1 ml Fogarty balloon-catheter were placed intraventricularly in the left ventricle (LV) to perform measurements at different preload LV volumes.
Determination of high energy phosphates
Adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) contents were assessed with standard photometry using an enzyme-kinetic assay (reagents provided by Sigma, Germany). After the haemodynamic measurements the heart were immediately frozen in liquid nitrogen. Therefore, the animal was placed about the cryo-cup and the heart was excised by scissors to minimize the number of contractions before being completely chilled. Energy charge potential was calculated as (ATPq0.5ADP)y(ATPqADPqAMP).
Statistical analysis
All values were expressed as mean"standard error of the mean (S.E.M.). Individual means between the groups were compared by one-way analysis of variance followed by an unpaired t-test with a Bonferroni correction for multiple comparisons and the post hoc Scheffe's test. A value of P-0.05 was considered statistically significant.
Results
The hemodynamic parameters after 60 min of reperfusion are shown in Table 2 significantly different between the groups. In comparison to the HTK and HTK-2 group, LVSP and minimum rate of pressure development (dPydt ) were significantly better min in the HTK-1 group (P-0.05). The LVEDP, myocardial high energy phosphate content and energy charge potential were on a comparable level and not significantly different between the three groups.
Discussion
The present study has demonstrated that in the heterotopic rat-heart-transplant model: (1) the new HTK-1 base solution with addition of N-a-acetyl-L-histidine is superior to classic HTK solution in protecting myocardial function and myocardial relaxation after ischemia and subsequent reperfusion; and (2) there was no additional protective effect of a fortification of the preservation solution (HTK-2) with iron-chelators deferoxamine and LK-614. The model of heterotopic rat-heart-transplantation with 1 h ischemia offers similar conditions of whole blood reperfusion as clinical heart transplantation. Furthermore, heterotopic rat-heart-transplantation allows to measure myocardial function independently from the actual loading conditions. The ischemic time was limited to 1 h because longer ischemic periods caused higher incidence of primary graft failure in the heterotopic rat heart model which prohibited comparable functional measurements.
Apart from the preservation of myocardial function w2x, the integrity of endothelial cell function is now increasingly recognized w3x. The key role for endothelial preservation in the pathogenesis of myocardial dysfunction after rat heart transplantation has been demonstrated by recent studies w3, 4x. Improper endothelial cell preservation can cause organ dysfunction by increased capillary permeability, tissue edema, by impaired vasoregulation and microvascular hypoperfusion w10x.
The hearts from deceased donors are subjected to a period of cold ischemia while been transported for transplantation. Storage in HTK solution effectively reduces the energy requirements of the tissue. Thus, HTK supports resumption of contractile function following reperfusion. Recently, an iron-dependent way in the formation of ROS has been documented by studies of Rauen and Huang. According to Rauen this injury is initiated specifically during cold ischemic storage. The cold-induced increase in chelatable, 'redox-active' iron leads to lipid peroxidation, a mitochondrial permeability transition, free radiacal-mediated cell injury and cold induced apoptosis in various cell types, including endothelial cells. Thus, the involvement of free radicals as important mediators of reperfusion injury of transplanted organs in cold storage induced injury is just being recognized w11x.
A number of recent studies have reported that storage of cells or organs in the cold may increase free radical production. Iron released during the cold may catalyse part of this free radical production. In experimental kidney transplantation, cold temperatures were demonstrated to cause marked release of iron from tubular cells w12x. In normal cells, free iron is nearly undetectable w12x. Free iron at higher levels catalyzes the Haber-Weiss-reaction, resulting in the generation of toxic hydroxyl radicals. The hydroxyl radical is one of the most cytotoxic free radicals because of its strong oxidizing properties, which scavenge nitric oxide, lead to lipid peroxidation of cell membranes and damage DNA w13x. Rauen described a major role of chelatable 'redox-active' iron in the development of cold induced apoptosis rat coronary endothelial cells w13x. There are no physiological defence mechanisms that can scavenge excessive amounts of hydoxyl radicals w13x. Thus, it is critically important to prevent the generation of these radical species by chelating the metal catalysts involved in their production. These findings suggest that the strategy of including deferoxamine in the cold HTK storage solution may reduce cold ischemic transplant injury w11x. The iron chelator deferoxamine has been shown to protect coldstored kidneys and cold-perfused hearts against injury caused by cold ischemiaywarm reperfusion w7x. Deferoxamine forms complexes with Fe ions and thereby decreasq 3 es formation of hydroxyl radicals. However, its hydrophilic nature and the high molecular weight limit the membrane permeability. Therefore, the newly developed LK-614 membrane permeable iron chelator is used as an additional additive. The HTK-2 solution with the addition of the ironchelators deferoxamine and LK-614 failed to prove a significant beneficial effect. This weaker protective effect may be explained by a deferoxamine-toxicity at high concentrations w13, 14x.
Apart from the iron-dependent compound of the cold induced injury, Rauen described a second line iron-independent, chloride mediated injury. This iron-independent component was sufficiently inhibited by a reduction of the extracellular chloride concentration in the storage solution w8x.
In the tested two modifications of the HTK solution, histidine was partially replaced by N-a-acetyl-histidine, the chloride concentration was lowered and in the HTK-2 solution the iron-chelators deferoxamine and LK-614 were added. The new HTK-1 solution with addition of N-a-acetyl-L-histidine offers better functional myocardial protection after long-term cold-ischemic storage than the classic HTK solution (Custodiol ) (Figs. 1 and 2) . The amino acid ᮋ histidine offers excellent buffer capacity and it was introduced in the classic HTK solution for prevention of severe tissue acidosis during cold storage. However, histidine and elevated intracellular levels of chelatable iron during hypothermia act synergistically to a strong enhancement of cold-induced injury. Therefore, a partial replacement of histidine with the non-toxic N-a-acetyl-histidine is an attractive alternative to prevent enhancement of cold induced cell injury w8x. Another explanation for impaired endothelial function after prolonged cold ischemic storage may be the depletion of L-arginine, the substrate for nitric oxide production w6x. The addition of L-arginine in the newly developed HTK formulations, especially in the HTK-1 solution may also be responsible for the better functional recovery of the grafts. The group of Szabó demonstrated a persistent beneficial effect after initial treatment with Larginine against reperfusion-induced graft coronary endothelial dysfunction w15x. But this study has some limitations in the fact that there were several changes in the formulation of the two modified HTK solutions. Further studies are needed to decide which of the components made the difference. The influence of the single components, chloride concentration, addition of L-argine and partial replacement of histidine needs to be further investigated.
In conclusion, the addition of iron-chelators deferoxamine and LK-614 in a relatively high concentration to storage solutions like HTK did not improve functional results to limit cold-ischemic injury. But the addition of N-a-acetyl-L-histidine and a reduction of chloride concentration of the HTK-1 solution improved these functional results and is a potential clinical strategy. The lack of any protection against iron-dependent injury in the classic HTK solution may be an explanation for an inferior protective effect and poorer functional results. The prevention of cold ischemic injury is a step necessary to improve functional results, to reduce immunogenity, to prevent chronic allograft vasculopathy and thus prolong allograft survival w12x.
